



Songdo Bio Campus Plant 1

Our cGMP-ready facility is designed to support efficient and flexible manufacturing, enabling streamlined tech transfer and scalable production from early-stage to commercial supply. Our capabilities are further strengthened by the acquisition of an establish U.S. facility, bringing in a highly experienced workforce integrated through cross-training. Combined with leadership and key experts from global CDMOs, we deliver agile and reliable execution.

Gravity Flow Design



Bioreactor Configuration



Future-Ready Manufacturing Facility



Real time data sharing

- Centralized data sharing through Customer Service Platform to enhance transparency and data-driven decision making



Optimized scale-up and tech transfer

- CFD-based scale-up strategy in biopharmaceuticals to enable quantitative and predictive process development



Seamless tech transfer between sites

- Veeva, SAP, IBM Maximo, LIMS data
- Real-time data sharing

Project Timeline & Progress

Mar, 2024
Kick-off

Jun, 2026
Mechanical Completion

Nov, 2026
GMP Readiness



Why LOTTE Biologics?

Quality & Regulatory Excellence



- Zero critical observations from FDA / PMDA inspections (2024)
- 98% batch success

Speed & Flexibility



- IND-ready from CLD within 10 months
- Flexible scheduling with readily available capacity

End-to-End Capabilities



- Integrated CDMO services from process development to commercial manufacturing

Cost Competitiveness



- Economies of scale driven by Songdo Bio Campus

Partnership Driven Culture



- 24/7 client communication and dedicated PM support
- Experienced team with deep understanding of clients' perspective

Dual-site Advantage



- Dual site operations in U.S. and S.Korea

Songdo, Korea

Global
Footprint

Syracuse, U.S.



www.lottebiologics.com